Progenics Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Tarrytown NY United States (1986)
Status: Acquired by Lantheus Medical Imaging (2019)

Organization Overview

First Clinical Trial
2002
NCT01367587
First Marketed Drug
2008
methylnaltrexone (relistor)
First NDA Approval
2008
methylnaltrexone (relistor)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Progenics Pharmaceuticals, Inc. | PROGENICS PHARMS INC | Vice President, Clinical Research, Progenics Pharmaceuticals, Inc.

Indications

Approved Indications


 

Constipation

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 2)

Adenocarcinoma (Phase 3)

Communicable Diseases (Phase 2)

Constipation (Phase 4)

Gastrointestinal Diseases (Phase 2)

Genital Neoplasms, Male (Phase 2)

Glioblastoma (Phase 2)

Gliosarcoma (Phase 2)

Hernia (Phase 3)

Hernia, Ventral (Phase 3)

HIV Infections (Phase 2)

Ileus (Phase 3)

Immunologic Deficiency Syndromes (Phase 2)

Infections (Phase 2)

Intestinal Diseases (Phase 2)

Liver Diseases (Phase 1)

Neoplasms (Phase 2)

Neoplasms by Site (Phase 2)

Neuroendocrine Tumors (Phase 2)

Prostatic Diseases (Phase 2)

Prostatic Neoplasms (Phase 3)

Recurrence (Phase 3)

Renal Insufficiency (Phase 1)

Urogenital Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 71
  • # of Trial APIs: 24